Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 695,000 ordinary shares of 25 pence each.
- Purchase Price: 1,431.0066 pence per share.
- Treasury Holdings: 195,191,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,791,005,766 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on September 20, 2006. This action was authorized by shareholders at the Annual General Meeting held on May 17, 2006. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying the 695,000 shares by the price of 1,431.0066 pence.
- Confirm the updated total share capital structure (5,791,005,766 issued shares plus 195,191,678 treasury shares).
- Review the May 17, 2006 Annual General Meeting minutes to confirm the scope of the share buyback authority utilized.